Neurodegenerative diseases are characterized by the progressive loss or dysfunction of cells in the brain &/or spinal cord. These diseases are especially devastating because the affected cells typically do not recover following damage or death. The search for effectively targeting and treating the root pathological cause responsible for disease initiation and progression has proven to be a challenge.
At SPARC, we reject this status quo.
Our approach to targeting neurodegeneration is to restore cellular homeostasis and stabilize cellular health and function. We believe there are multiple ways to achieve this: reducing oxidative stress; modulating autophagic flux; and/or preventing aggregation of misfolded proteins, including potential combinatorial therapies to achieve this goal.
Our lead therapeutic agent, vodobatinib (SCC-138) is a c-ABL inhibitor that has the potential to be a first-in-class therapy modulating cellular homeostasis in neurodegenerative diseases. Based on new breakthroughs in neuroscience, we are targeting novel pathways to develop disease-modifying agents for the treatment of patients with neurodegenerative diseases.